Given a coronary artery calcium score of 7, an LDL cholesterol of 116 mg/dL, and a 10‑year ASCVD (atherosclerotic cardiovascular disease) risk of 3.4 %, what is the appropriate management?

Statin Therapy is Recommended for This Patient

With a coronary artery calcium (CAC) score of 7, LDL-C of 116 mg/dL, and a 10-year ASCVD risk of 3.4%, this patient should initiate moderate-intensity statin therapy. The presence of any detectable coronary calcium (CAC > 0) in a borderline-risk patient significantly reclassifies their risk upward and warrants treatment.

Risk Reclassification Based on CAC Score

Your patient falls into the borderline ASCVD risk category (3.4% 10-year risk, which is <5%). However, the CAC score of 7 fundamentally changes the clinical picture:

• Patients with borderline risk and CAC = 0 have only a 1.5% 10-year ASCVD risk 1
• Patients with borderline risk and CAC > 0 have a 7.4% 10-year ASCVD risk 1—essentially doubling their risk and moving them into a range where statin benefit clearly outweighs risk

This patient's CAC score of 7 confirms the presence of coronary atherosclerotic plaque, indicating subclinical disease that the risk calculator alone underestimated. The calcium score effectively reclassifies this patient from borderline to intermediate risk.

Treatment Algorithm for CAC Score 1-99

For patients with CAC scores between 1-99 (which includes your patient's score of 7):

• Moderate-intensity statin therapy is favored, particularly for patients aged >55 years 1
• The intermediate-risk group with CAC > 0 had an observed 10-year event rate of 10.4% in MESA analyses, supporting statin recommendation 1
• Statin treatment is reasonable to initiate for patients ≥55 years of age with CAC 1-99 2

LDL-C Target and Intensity

With an LDL-C of 116 mg/dL, this patient has room for meaningful reduction:

• Moderate-intensity statin therapy (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg, or simvastatin 20-40 mg) typically lowers LDL-C by 30-50%
• This would bring LDL-C to approximately 58-81 mg/dL, which is appropriate for primary prevention with documented atherosclerosis
• No specific LDL-C target is mandated by current guidelines, but the presence of CAC justifies aggressive risk factor modification 1

Additional Management Considerations

Beyond statin therapy, this patient requires:

• Aggressive lifestyle modification: The presence of CAC should be used as a motivational tool—patients with detectable calcium are more likely to adhere to preventive therapies when they understand they have measurable disease 1
• Address all modifiable risk factors: blood pressure control, smoking cessation if applicable, diabetes management if present
• Aspirin consideration: While not universally recommended in primary prevention, some guidelines suggest aspirin 81 mg daily for CAC ≥100 3; at CAC = 7, this remains a shared decision-making discussion

Follow-Up Strategy

• Reassess in 3-5 years if the patient or clinician remains uncertain about continuing therapy, though with documented CAC, ongoing treatment is strongly favored 1
• Do not repeat CAC scoring routinely—the presence of calcium is established, and serial scanning has limited value at this score range 1
• Monitor for statin-associated symptoms but recognize that the absolute benefit (preventing ASCVD events) far outweighs the small risk of adverse effects in this patient

Common Pitfalls to Avoid

1. Do not defer treatment based solely on the low calculated risk score (3.4%)—the CAC score provides patient-specific data that supersedes population-based risk estimates
2. Do not wait for symptoms—this patient has asymptomatic atherosclerosis that will progress without intervention
3. Do not order stress testing or coronary angiography—there is no indication for ischemia evaluation in asymptomatic patients with low CAC scores 1
4. Do not dismiss the significance of "low" calcium scores—even CAC scores of 1-10 indicate established atherosclerotic disease and increased risk

The evidence strongly supports that any detectable coronary calcium in a patient with borderline risk warrants statin therapy to prevent future cardiovascular events 1.